

Next Day Disclosure Return
(Equity issuer - changes in issued share capital and/or share buybacks)

Name of listed issuer: Genscript Biotech Corporation (the “Company”)

Stock code: 1548

Date submitted: 19 May 2017

Section I must be completed by a listed issuer where there has been a change in its issued share capital which is discloseable pursuant to rule 13.25A of the Rules (the “Listing Rules”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Exchange”).

Section II must also be completed by a listed issuer where it has made a repurchase of shares which is discloseable under rule 10.06(4)(a).

Description of securities: Ordinary Shares

I.					
Issues of shares (Notes 6 and 7)	No. of shares	Issued shares as a % of existing number of issued shares before relevant share issue (Notes 4, 6 and 7)	Issue price per share (Notes 1 and 7)	Closing market price per share of the immediately preceding business day (Note 5)	% discount/ premium of issue price to market price (Note 7)
Opening balance as at (Note 2) <u>30 April 2017</u>	1,708,886,761				
(Note 3)					
Exercise of share options pursuant to the Pre-IPO share option scheme adopted on 15 July 2015 by eligible employees of the Company on 2 May 2017	9,717	0.0006%	HK\$0.798	HK\$3.46 (as of 28 April 2017)	76.936% discount
Exercise of share options pursuant to the Pre-IPO share option scheme adopted on 15 July 2015 by eligible employees of the Company on 12 May 2017	100,000	0.0059%	HK\$0.023	HK\$3.45 (as of 11 May 2017)	99.333% discount

For Main Board listed issuers

Exercise of share options pursuant to the Pre-IPO share option scheme adopted on 15 July 2015 by eligible employees of the Company on 15 May 2017	940,489	0.0550%	HK\$0.734	HK\$3.48 (as of 12 May 2017)	78.908% discount
Exercise of share options pursuant to the Pre-IPO share option scheme adopted on 15 July 2015 by eligible employees of the Company on 16 May 2017	158,664	0.0093%	HK\$0.597	HK\$4.13 (as of 15 May 2017)	85.545% discount
Exercise of share options pursuant to the Pre-IPO share option scheme adopted on 15 July 2015 by eligible director of the Company on 17 May 2017	680,000	0.0398%	HK\$0.597	HK\$3.99 (as of 16 May 2017)	85.038% discount
Share repurchases	Not applicable	Not applicable			
Closing balance as at (Note 8) <u>17 May 2017</u>	1,710,775,631				

Notes to Section I:

- Where shares have been issued at more than one issue price per share, a weighted average issue price per share should be given.
- Please insert the closing balance date of the last Next Day Disclosure Return published pursuant to rule 13.25A or Monthly Return pursuant to rule 13.25B, whichever is the later.
- Please set out all changes in issued share capital requiring disclosure pursuant to rule 13.25A together with the relevant dates of issue. Each category will need to be disclosed individually with sufficient information to enable the user to identify the relevant category in the listed issuer's Monthly Return. For example, multiple issues of shares as a result of multiple exercises of share options under the same share option scheme or of multiple conversions under the same convertible note must be aggregated and disclosed as one category. However, if the issues resulted from exercises of share options under 2 share option schemes or conversions of 2 convertible notes, these must be disclosed as 2 separate categories.
- The percentage change in the number of issued shares of listed issuer is to be calculated by reference to the listed issuer's total number of shares in issue (excluding for such purpose any shares repurchased or redeemed but not yet cancelled) as it was immediately before the earliest relevant event which has not been disclosed in a Monthly Return or Next Day Disclosure Return.
- Where trading in the shares of the listed issuer has been suspended, "closing market price per share of the immediately preceding business day" should be construed as "closing market price per share of the business day on which the shares were last traded".

6. *In the context of a repurchase of shares:*
 - *“issues of shares” should be construed as “repurchases of shares”; and*
 - *“issued shares as a % of existing number of shares before relevant share issue” should be construed as “repurchased shares as a % of existing number of shares before relevant share repurchase”.*
7. *In the context of a redemption of shares:*
 - *“issues of shares” should be construed as “redemptions of shares”;*
 - *“issued shares as a % of existing number of shares before relevant share issue” should be construed as “redeemed shares as a % of existing number of shares before relevant share redemption”; and*
 - *“issue price per share” should be construed as “redemption price per share”.*
8. *The closing balance date is the date of the last relevant event being disclosed.*

II.

A. Purchase report

Trading date	Number of securities purchased	Method of purchase (Note)	Price per share or highest price paid \$	Lowest price paid \$	Total paid \$
	_____				_____
Total	_____				_____

B. Additional information for issuer whose primary listing is on the Exchange

1. Number of such securities purchased on the Exchange in the year to date (since ordinary resolution) (a) _____
2. % of number of shares in issue at time ordinary resolution passed acquired on the Exchange since % date of resolution _____
- ((a) x 100)
Number of shares in issue

We hereby confirm that the repurchases set out in A above which were made on the Exchange were made in accordance with the Listing Rules and that there have been no material changes to the particulars contained in the Explanatory Statement dated _____ which has been filed with the Exchange. We also confirm that any purchases set out in A above which were made on another stock exchange were made in accordance with the domestic rules applying to purchases made on that other exchange.

Note to Section II: Please state whether on the Exchange, on another stock exchange (stating the name of the exchange), by private arrangement or by general offer.

Submitted by: Meng Jiange
(Name)

Title: Director
(Director, Secretary or other duly authorised office)